Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2022
2023
2024
2025
Iovance Biotherapeutics, Inc. (IOVA)
Price$8.79Cached quote
Net income
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $263.5M | $164.1M | $1.2M | $0 | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Gross profit | $90.3M | $70.8M | $156,000 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross margin | 34.28% | 43.17% | 13.12% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $300.3M | $276.2M | $333.2M | $294.8M | $259.0M | $201.7M | $166.0M | $99.8M | $71.6M | $26.9M | $15.5M | $3.8M | $2.2M | $1.7M | $1.8M | $171,484 | $0 | — |
| Operating expenses | $666.9M | $559.3M | $461.7M | $398.9M | $342.7M | $261.9M | $206.9M | $128.3M | $92.9M | $53.6M | $27.9M | $12.0M | $22.6M | $8.1M | $21.2M | $815,413 | $15,772 | — |
| Operating income | −$403.4M | −$395.3M | −$460.6M | −$398.9M | −$342.7M | −$261.9M | −$206.9M | −$128.3M | −$92.9M | −$53.6M | −$27.9M | −$12.0M | −$22.6M | −$8.1M | −$21.2M | −$815,413 | −$15,772 | — |
| Operating margin | −153.08% | −240.92% | −38,734.99% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −$390.5M | −$384.0M | −$449.0M | −$389.6M | −$339.6M | −$260.8M | −$205.7M | −$127.3M | −$91.9M | −$52.7M | −$26.9M | −$12.0M | −$22.6M | −$8.1M | −$21.2M | −$756,816 | −$14,440 | — |
| EBITDA margin | −148.19% | −234.06% | −37,762.07% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$391.0M | −$372.2M | −$444.0M | −$395.9M | −$342.3M | −$259.6M | −$197.6M | −$123.6M | −$92.1M | −$52.9M | −$27.7M | −$12.0M | −$25.4M | −$3.3M | −$25.7M | −$1.6M | −$15,772 | −$58,716 |
| Net profit margin | −148.38% | −226.84% | −37,345.42% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$1.09 | -$1.28 | -$1.89 | -$2.49 | -$2.23 | -$1.88 | -$1.59 | -$1.27 | -$1.41 | -$1.85 | -$0.62 | -$0.48 | -$3.47 | -$4.14 | -$34.00 | -$2.00 | $0.00 | — |
| Diluted EPSper diluted share | -$1.09 | -$1.28 | -$1.89 | -$2.49 | -$2.23 | -$1.88 | -$1.59 | -$1.27 | -$1.41 | -$1.85 | -$0.62 | -$0.48 | -$3.47 | -$4.14 | -$34.00 | -$2.00 | $0.00 | — |
Owners
Reported shareholders
8.16%of listed shares
BlackRock, Inc.36.96M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 8.16%36.96M shares |
MHR FUND MANAGEMENT LLC | 6.39%28.97M shares |
STATE STREET CORP | 5.40%24.48M shares |
TWO SIGMA INVESTMENTS, LP | 4.20%19.01M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.02%18.2M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.18%14.39M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.28%10.32M shares |
MILLENNIUM MANAGEMENT LLC | 1.88%8.53M shares |
DIMENSIONAL FUND ADVISORS LP | 1.43%6.46M shares |
Palo Alto Investors LP | 1.17%5.3M shares |
GOLDMAN SACHS GROUP INC | 1.13%5.1M shares |
Nuveen, LLC | 1.10%5M shares |
BANK OF AMERICA CORP /DE/ | 1.10%4.99M shares |
MORGAN STANLEY | 1.10%4.99M shares |
JUPITER ASSET MANAGEMENT LTD | 1.00%4.54M shares |
JANE STREET GROUP, LLC | 0.97%4.39M shares |
NORTHERN TRUST CORP | 0.92%4.15M shares |
AQR CAPITAL MANAGEMENT LLC | 0.85%3.87M shares |
WELLS FARGO & COMPANY/MN | 0.72%3.25M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.71%3.22M shares |
Percentages use 452.97M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 5, 2025Form 4 | Kirby Daniel GordonChief Commercial Officer | BuyCommon Stock | 30.0K | $1.84 | $55.2K | 30.0K |
| May 23, 2025Form 4 | Puri Raj K.Chief Regulatory Officer | BuyCommon Stock | 5.6K | $1.74 | $9.7K | 206.9K |
| May 14, 2025Form 4 | Vogt Frederick GInterim CEO & General Counsel | BuyCommon Stock | 25.0K | $1.69 | $42.3K | 374.6K |
| Nov 12, 2024Form 4 | Maynard Ryan DDirector | SellCommon Stock | 50.0K | $10.06 | $503.0K | 7.5K |